Clinical Trial

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Study acronym: TRONTIER 1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Protocol Amendment History 2 changes
notable Trial sites expanded: 134 -> 141 locations 2026-05-05
notable Trial sites expanded: 120 -> 134 locations 2026-04-04
Trial Details
NCT Number NCT07169578
Lead Sponsor Hoffmann-La Roche
Conditions Alzheimers Disease
Enrollment 800 participants
Start Date 2025-09-17
Primary Completion 2028-06-07 (estimated)
Study Completion 2028-06-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-02